Welcome to our dedicated page for Veeva Sys news (Ticker: VEEV), a resource for investors and traders seeking the latest updates and insights on Veeva Sys stock.
Veeva Systems (VEEV) delivers cloud solutions transforming life sciences operations through CRM, quality management, and regulatory compliance tools. This news hub provides investors and industry professionals with essential updates on the company's strategic developments.
Access real-time announcements including quarterly earnings, product innovations, and strategic partnerships. Our curated collection features press releases about Veeva Vault implementations, AI-enhanced CRM capabilities, and compliance milestones critical for pharmaceutical and biotech organizations.
Bookmark this page for verified updates on clinical trial management advancements, quality control system upgrades, and regulatory submissions supported by Veeva's industry-specific platforms. Stay informed about developments impacting life sciences technology landscapes through our neutral, comprehensive reporting.
Veeva Systems reported a strong second quarter for fiscal 2022, with total revenues of $455.6 million, marking a 29% year-over-year increase. Subscription services revenues also rose to $366.4 million, up 29%. Operating income was $124.6 million, a 38% increase compared to the prior year. Non-GAAP net income increased by 31% to $152.7 million, with diluted net income per share at $0.67. Veeva's outlook for the third quarter projects revenues between $464 and $466 million and for the fiscal year, between $1,830 and $1,835 million.
Veeva Systems (NYSE: VEEV) announces that B. Braun SE has adopted the Veeva Vault Clinical Operations Suite to enhance clinical study management and payments to partner sites globally. This collaboration aims to improve efficiency and oversight in clinical trials, allowing B. Braun to conduct more studies at a faster pace. The integration includes Veeva's solutions for study management and payments, aiding compliance and reducing administrative burdens. The partnership signifies a step in B. Braun's digital transformation and commitment to advancing healthcare.
Veeva Systems will release its financial results for the second fiscal quarter, concluding on July 31, 2021, after market close on September 1, 2021. A conference call and webcast will be held on the same day at 2:00 p.m. PT (5:00 p.m. ET) to discuss the results. Prepared remarks will be available on Veeva's investor relations website around 1:05 p.m. PT (4:05 p.m. ET). This quarterly release comes as Veeva continues to serve over 1,000 customers globally in the life sciences sector.
Veeva Systems (NYSE: VEEV) announced its acquisition of Learnaboutgmp, a premier provider of accredited GxP training for life sciences, on August 3, 2021. This acquisition combines Learnaboutgmp's extensive eLearning library, featuring over 170 course titles and 450 microlearning assets, with Veeva's Vault Training, enhancing training efficiency and compliance for clients. Learnaboutgmp will continue its operations independently under its founder, maintaining its presence in both Ireland and the United States, while aiming to address growing compliance needs in the industry.
Veeva Systems announced the addition of 11 new therapeutic areas to its customer intelligence platform, Veeva Link, now covering 12 areas including oncology. The platform provides curated expert profiles and real-time insights to enhance engagement between life sciences teams and global experts. Key areas expanded include cardiology, neurology, and respiratory diseases. Veeva aims to set the industry standard in real-time customer intelligence, supporting better research and patient care. A summit on June 10, 2021, will showcase how Veeva Link aids pharma companies in personalizing customer interactions.
Veeva Systems (NYSE: VEEV) announced the upcoming 2021 Veeva Commercial & Medical North America Summit Connect on June 10, 2021, featuring keynotes from industry leaders at Boehringer Ingelheim, GSK, and UCB. The event will explore digital-first engagement and data innovation approaches. Dr. Cecil T. Holbert and Amanda Romano will open with a discussion on evolving healthcare provider access. There will be over 100 sessions focused on transforming commercial strategies in the life sciences sector.
Veeva Systems reported strong fiscal 2022 Q1 results, achieving total revenues of $433.6 million, a 29% increase year-over-year. Subscription services revenues grew by 26% to $341.1 million. Operating income rose 47% to $128.4 million, with net income increasing 33% to $115.6 million. Non-GAAP metrics showed similar growth, with non-GAAP net income per share reaching $0.91. The company added a record 59 new customers, bringing the total to over 1,000. Veeva's outlook for Q2 anticipates revenues of $450-$452 million, with non-GAAP net income per share projected at $0.85-$0.86.
The Shareholder Commons is advocating for shareholder proposals to compel companies to become Public Benefit Corporations (PBCs), which integrate social and environmental goals with profit. Support for this initiative is growing, backed by governance advisors like PIRC Limited. Significant votes are pending at large firms such as Chevron, BlackRock, and Alphabet. Proponents argue that a legally binding commitment to balance stakeholder interests can protect investor value. Veeva Systems is highlighted as the largest publicly traded PBC, reflecting a shift in corporate purpose.
Veeva Systems (NYSE: VEEV) announced that over 100 organizations have implemented Veeva Vault Training to enhance role-based qualification and comply with industry standards. This integration with Veeva Vault QualityDocs facilitates streamlined document and training management. Customers benefit from features such as seamless learning management, sophisticated curriculum builds, and robust reporting. Veeva aims to address evolving training needs in life sciences, fostering efficiency and compliance across the industry.
On May 19, 2021, Veeva Systems (NYSE: VEEV) announced an increasing adoption of its Veeva Development Cloud by over 650 life sciences companies. This platform integrates applications for clinical, regulatory, quality, and safety functions, designed to eliminate organizational silos and enhance collaboration. Notably, more than 350 companies are using Vault Clinical applications, while more than 250 are optimizing regulatory processes with Vault RIM. The company emphasizes accelerating drug development and improving operational efficiency through its unified applications.